Clinical Trials on Paramyxoviridae Infections in New Zealand

Total 6556 results

Restorbio Inc.

Completed

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Respiratory Tract Infections

New Zealand
Assembly Biosciences

Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

New Zealand
National Institute of Allergy and Infectious Diseases...

Terminated

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

Respiratory Syncytial Virus Infections

United States
Arrowhead Pharmaceuticals

Terminated

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Hepatitis B

New Zealand
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
LumiraDx UK Limited

Recruiting

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites (INSPIRE)

Influenza, Human | Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
MedImmune LLC

Terminated

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Healthy

United States
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Respiratory Syncytial Virus Infection

United States, France, Sweden, Korea, Republic of, Switzerland
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Respiratory Syncytial Virus Infections | Chronic Lung Disease and <= 24 Months of Age or | Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Australia, Chile, New Zealand
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Pfizer

Recruiting

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Respiratory Syncytial Virus Infections

United States, Israel, Japan, Korea, Republic of, South Africa, Argentina, Canada
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Novira Therapeutics, Inc.

Completed

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Chronic Hepatitis B

New Zealand
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...
Merck Sharp & Dohme LLC

Completed

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

HIV Infections | Measles

United States, Puerto Rico
Assembly Biosciences

Completed

A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects

Chronic Hepatitis B

New Zealand
Pardes Biosciences, Inc.

Completed

Study of PBI-0451 in Healthy Subjects.

Covid19

New Zealand
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Australia, New Zealand
University of Auckland, New Zealand

Completed

Humidification in Laparoscopic Colonic Surgery

Peritoneal Inflammation

New Zealand
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
AlloVir

Terminated

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Influenza Infection | Respiratory Tract Viral Infections | Human Metapneumovirus (hMPV) Infection | Parainfluenza (PIV) Infection | Respiratory Syncytial Viral (RSV) Infection

United States
Murdoch Childrens Research Institute
Royal Children's Hospital

Recruiting

Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (CHOICE UTI)

Infection | Pediatric Infectious Disease | Complicated Urinary Tract Infection

Australia, New Zealand
National Institute of Allergy and Infectious Diseases...

Terminated

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Measles | Rubella | Mumps | Varicella

United States
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral Infection

United States, New Zealand
Alnylam Pharmaceuticals

Completed

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia, Austria, Canada, France, Germany
GlaxoSmithKline

Terminated

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Australia, France, Finland, Taiwan, Spain, Philippines, Mexico, Belgium, Italy, Panama, New Zealand, Thailand, Brazil, Canada, India, Colombia, Korea, Republic of, United Kingdom, South Africa, Argentina, Bangladesh, Dominican... and more
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Canada, Japan, Germany, Australia, South Africa
AstraZeneca

Completed

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

United States, France, Italy, Spain, Belgium, Russian Federation, Poland, Turkey, New Zealand, Austria, Korea, Republic of, Germany, Hungary, Bulgaria, Ukraine, South Africa, Japan, Estonia, Lithuania, United Kingdom, Canada, Czechia and more
Alnylam Pharmaceuticals

Completed

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia
GlaxoSmithKline

Completed

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Sweden
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Infections, Respiratory Syncytial Virus

United States
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
GlaxoSmithKline

Active, not recruiting

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults (RSV-OA=ADJ-020)

Respiratory Syncytial Virus Infections | Respiratory Syncytial Viruses

United States, Canada

3

Subscribe